Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis
Background Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve outcomes of patients with type 2 diabetes at high cardiovascular risk and chronic kidney disease. Recent studies showed an increase in hemoglobin and hematocrit after SGLT2i treatment. Materials and methods We did a systematic rev...
Gespeichert in:
| Veröffentlicht in: | International urology and nephrology 2022-04, Vol.54 (4), p.827-841 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 841 |
|---|---|
| container_issue | 4 |
| container_start_page | 827 |
| container_title | International urology and nephrology |
| container_volume | 54 |
| creator | Kanbay, Mehmet Tapoi, Laura Ureche, Carina Tanriover, Cem Cevik, Enes Demiray, Atalay Afsar, Baris Cherney, David Z. I. Covic, Adrian |
| description | Background
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve outcomes of patients with type 2 diabetes at high cardiovascular risk and chronic kidney disease. Recent studies showed an increase in hemoglobin and hematocrit after SGLT2i treatment.
Materials and methods
We did a systematic review and meta-analysis of randomized, double-blind, placebo-controlled studies of SGLT2i in patients with type 2 diabetes. We searched through PubMed/Medline, Web of Science, Embase (Elsevier), and the Cochrane Central Register of Controlled Trials (Wiley) from January 2010 to January 2021.
Results
We included seventeen randomized, double-blind, placebo-controlled studies. The total number of evaluated patients was 14,748. The treatment arm consisted of canagliflozin, dapagliflozin, empagliflozin and ipragliflozin. SGLT2i therapy significantly increased hemoglobin levels when compared to placebo (MD 5.60 g/L, 95% CI 3.73–7.47 g/L,
P
|
| doi_str_mv | 10.1007/s11255-021-02943-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2552989995</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2552989995</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-161e8d7d56f0c7fcb6c0501ed927e6e4ededddc325781992679e53c2d9d8a85b3</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS1ERaeFF-gCWWLDJq1_4iRmh6rSVqrEBtaWY99MXSXx4OsUzY536Bv2SfB0WpBYsLBs637nXF8fQk44O-WMtWfIuVCqYoKXpWtZiVdkxVVbDqqrX5MVk4xXvBHykBwh3jHGdMfYG3Ioa9FK1rAVebgYBnCZxoFi9GGZHn89rMfFRQTqYk52xk1MGRIVNMy3oQ85JqRxprcwxfUY-zBTO_vd1eboUsh0hHsYseA0bzdQhD7YHjLgJ2opbjHv0OBogvsAP5_UE2Rb2dmOWwz4lhwMdkR497wfk-9fLr6dX1U3Xy-vzz_fVK6ueS6Dceh861UzMNcOrm8cU4yD16KFBmrw4L13Uqi241qLptWgpBNe-852qpfH5OPed5PijwUwmymgg3G0M8QFTflcoTuttSroh3_Qu7ik8t5CNVJzUddSFErsKZciYoLBbFKYbNoazswuMrOPzJTIzFNkZid6_2y99BP4P5KXjAog9wCW0ryG9Lf3f2x_A-aNpJs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2639124432</pqid></control><display><type>article</type><title>Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Kanbay, Mehmet ; Tapoi, Laura ; Ureche, Carina ; Tanriover, Cem ; Cevik, Enes ; Demiray, Atalay ; Afsar, Baris ; Cherney, David Z. I. ; Covic, Adrian</creator><creatorcontrib>Kanbay, Mehmet ; Tapoi, Laura ; Ureche, Carina ; Tanriover, Cem ; Cevik, Enes ; Demiray, Atalay ; Afsar, Baris ; Cherney, David Z. I. ; Covic, Adrian</creatorcontrib><description>Background
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve outcomes of patients with type 2 diabetes at high cardiovascular risk and chronic kidney disease. Recent studies showed an increase in hemoglobin and hematocrit after SGLT2i treatment.
Materials and methods
We did a systematic review and meta-analysis of randomized, double-blind, placebo-controlled studies of SGLT2i in patients with type 2 diabetes. We searched through PubMed/Medline, Web of Science, Embase (Elsevier), and the Cochrane Central Register of Controlled Trials (Wiley) from January 2010 to January 2021.
Results
We included seventeen randomized, double-blind, placebo-controlled studies. The total number of evaluated patients was 14,748. The treatment arm consisted of canagliflozin, dapagliflozin, empagliflozin and ipragliflozin. SGLT2i therapy significantly increased hemoglobin levels when compared to placebo (MD 5.60 g/L, 95% CI 3.73–7.47 g/L,
P
< 0.00001, considerable heterogeneity—
I
2
= 94%). Each SGLT2i also led to a significant increase in the hematocrit level when compared to placebo (MD 1.32%, 95% CI 1.21–1.44,
P
< 0.00001, considerable heterogeneity—
I
2
= 99%).
Conclusions
SGLT2i led to significant increases in hemoglobin and hematocrit levels when compared to placebo. In addition to their cardiovascular effect, SGLT2i also increases hemoglobin and hematocrit levels.</description><identifier>ISSN: 0301-1623</identifier><identifier>EISSN: 1573-2584</identifier><identifier>DOI: 10.1007/s11255-021-02943-2</identifier><identifier>PMID: 34273060</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Cardiovascular diseases ; Clinical trials ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Hematocrit ; Hemoglobin ; Hemoglobins - metabolism ; Humans ; Hypoglycemic Agents - therapeutic use ; Kidney diseases ; Medicine ; Medicine & Public Health ; Meta-analysis ; Na+/glucose cotransporter ; Nephrology ; Nephrology - Review ; Patients ; Placebos ; Randomized Controlled Trials as Topic ; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use ; Systematic review ; Urology</subject><ispartof>International urology and nephrology, 2022-04, Vol.54 (4), p.827-841</ispartof><rights>The Author(s), under exclusive licence to Springer Nature B.V. 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Nature B.V.</rights><rights>The Author(s), under exclusive licence to Springer Nature B.V. 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-161e8d7d56f0c7fcb6c0501ed927e6e4ededddc325781992679e53c2d9d8a85b3</citedby><cites>FETCH-LOGICAL-c441t-161e8d7d56f0c7fcb6c0501ed927e6e4ededddc325781992679e53c2d9d8a85b3</cites><orcidid>0000-0002-1297-0675</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11255-021-02943-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11255-021-02943-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34273060$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kanbay, Mehmet</creatorcontrib><creatorcontrib>Tapoi, Laura</creatorcontrib><creatorcontrib>Ureche, Carina</creatorcontrib><creatorcontrib>Tanriover, Cem</creatorcontrib><creatorcontrib>Cevik, Enes</creatorcontrib><creatorcontrib>Demiray, Atalay</creatorcontrib><creatorcontrib>Afsar, Baris</creatorcontrib><creatorcontrib>Cherney, David Z. I.</creatorcontrib><creatorcontrib>Covic, Adrian</creatorcontrib><title>Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis</title><title>International urology and nephrology</title><addtitle>Int Urol Nephrol</addtitle><addtitle>Int Urol Nephrol</addtitle><description>Background
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve outcomes of patients with type 2 diabetes at high cardiovascular risk and chronic kidney disease. Recent studies showed an increase in hemoglobin and hematocrit after SGLT2i treatment.
Materials and methods
We did a systematic review and meta-analysis of randomized, double-blind, placebo-controlled studies of SGLT2i in patients with type 2 diabetes. We searched through PubMed/Medline, Web of Science, Embase (Elsevier), and the Cochrane Central Register of Controlled Trials (Wiley) from January 2010 to January 2021.
Results
We included seventeen randomized, double-blind, placebo-controlled studies. The total number of evaluated patients was 14,748. The treatment arm consisted of canagliflozin, dapagliflozin, empagliflozin and ipragliflozin. SGLT2i therapy significantly increased hemoglobin levels when compared to placebo (MD 5.60 g/L, 95% CI 3.73–7.47 g/L,
P
< 0.00001, considerable heterogeneity—
I
2
= 94%). Each SGLT2i also led to a significant increase in the hematocrit level when compared to placebo (MD 1.32%, 95% CI 1.21–1.44,
P
< 0.00001, considerable heterogeneity—
I
2
= 99%).
Conclusions
SGLT2i led to significant increases in hemoglobin and hematocrit levels when compared to placebo. In addition to their cardiovascular effect, SGLT2i also increases hemoglobin and hematocrit levels.</description><subject>Cardiovascular diseases</subject><subject>Clinical trials</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Hematocrit</subject><subject>Hemoglobin</subject><subject>Hemoglobins - metabolism</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Kidney diseases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meta-analysis</subject><subject>Na+/glucose cotransporter</subject><subject>Nephrology</subject><subject>Nephrology - Review</subject><subject>Patients</subject><subject>Placebos</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Sodium-Glucose Transporter 2 Inhibitors - therapeutic use</subject><subject>Systematic review</subject><subject>Urology</subject><issn>0301-1623</issn><issn>1573-2584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kc1u1DAUhS1ERaeFF-gCWWLDJq1_4iRmh6rSVqrEBtaWY99MXSXx4OsUzY536Bv2SfB0WpBYsLBs637nXF8fQk44O-WMtWfIuVCqYoKXpWtZiVdkxVVbDqqrX5MVk4xXvBHykBwh3jHGdMfYG3Ioa9FK1rAVebgYBnCZxoFi9GGZHn89rMfFRQTqYk52xk1MGRIVNMy3oQ85JqRxprcwxfUY-zBTO_vd1eboUsh0hHsYseA0bzdQhD7YHjLgJ2opbjHv0OBogvsAP5_UE2Rb2dmOWwz4lhwMdkR497wfk-9fLr6dX1U3Xy-vzz_fVK6ueS6Dceh861UzMNcOrm8cU4yD16KFBmrw4L13Uqi241qLptWgpBNe-852qpfH5OPed5PijwUwmymgg3G0M8QFTflcoTuttSroh3_Qu7ik8t5CNVJzUddSFErsKZciYoLBbFKYbNoazswuMrOPzJTIzFNkZid6_2y99BP4P5KXjAog9wCW0ryG9Lf3f2x_A-aNpJs</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Kanbay, Mehmet</creator><creator>Tapoi, Laura</creator><creator>Ureche, Carina</creator><creator>Tanriover, Cem</creator><creator>Cevik, Enes</creator><creator>Demiray, Atalay</creator><creator>Afsar, Baris</creator><creator>Cherney, David Z. I.</creator><creator>Covic, Adrian</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1297-0675</orcidid></search><sort><creationdate>20220401</creationdate><title>Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis</title><author>Kanbay, Mehmet ; Tapoi, Laura ; Ureche, Carina ; Tanriover, Cem ; Cevik, Enes ; Demiray, Atalay ; Afsar, Baris ; Cherney, David Z. I. ; Covic, Adrian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-161e8d7d56f0c7fcb6c0501ed927e6e4ededddc325781992679e53c2d9d8a85b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cardiovascular diseases</topic><topic>Clinical trials</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Hematocrit</topic><topic>Hemoglobin</topic><topic>Hemoglobins - metabolism</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Kidney diseases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meta-analysis</topic><topic>Na+/glucose cotransporter</topic><topic>Nephrology</topic><topic>Nephrology - Review</topic><topic>Patients</topic><topic>Placebos</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Sodium-Glucose Transporter 2 Inhibitors - therapeutic use</topic><topic>Systematic review</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kanbay, Mehmet</creatorcontrib><creatorcontrib>Tapoi, Laura</creatorcontrib><creatorcontrib>Ureche, Carina</creatorcontrib><creatorcontrib>Tanriover, Cem</creatorcontrib><creatorcontrib>Cevik, Enes</creatorcontrib><creatorcontrib>Demiray, Atalay</creatorcontrib><creatorcontrib>Afsar, Baris</creatorcontrib><creatorcontrib>Cherney, David Z. I.</creatorcontrib><creatorcontrib>Covic, Adrian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International urology and nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kanbay, Mehmet</au><au>Tapoi, Laura</au><au>Ureche, Carina</au><au>Tanriover, Cem</au><au>Cevik, Enes</au><au>Demiray, Atalay</au><au>Afsar, Baris</au><au>Cherney, David Z. I.</au><au>Covic, Adrian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis</atitle><jtitle>International urology and nephrology</jtitle><stitle>Int Urol Nephrol</stitle><addtitle>Int Urol Nephrol</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>54</volume><issue>4</issue><spage>827</spage><epage>841</epage><pages>827-841</pages><issn>0301-1623</issn><eissn>1573-2584</eissn><abstract>Background
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve outcomes of patients with type 2 diabetes at high cardiovascular risk and chronic kidney disease. Recent studies showed an increase in hemoglobin and hematocrit after SGLT2i treatment.
Materials and methods
We did a systematic review and meta-analysis of randomized, double-blind, placebo-controlled studies of SGLT2i in patients with type 2 diabetes. We searched through PubMed/Medline, Web of Science, Embase (Elsevier), and the Cochrane Central Register of Controlled Trials (Wiley) from January 2010 to January 2021.
Results
We included seventeen randomized, double-blind, placebo-controlled studies. The total number of evaluated patients was 14,748. The treatment arm consisted of canagliflozin, dapagliflozin, empagliflozin and ipragliflozin. SGLT2i therapy significantly increased hemoglobin levels when compared to placebo (MD 5.60 g/L, 95% CI 3.73–7.47 g/L,
P
< 0.00001, considerable heterogeneity—
I
2
= 94%). Each SGLT2i also led to a significant increase in the hematocrit level when compared to placebo (MD 1.32%, 95% CI 1.21–1.44,
P
< 0.00001, considerable heterogeneity—
I
2
= 99%).
Conclusions
SGLT2i led to significant increases in hemoglobin and hematocrit levels when compared to placebo. In addition to their cardiovascular effect, SGLT2i also increases hemoglobin and hematocrit levels.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>34273060</pmid><doi>10.1007/s11255-021-02943-2</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-1297-0675</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-1623 |
| ispartof | International urology and nephrology, 2022-04, Vol.54 (4), p.827-841 |
| issn | 0301-1623 1573-2584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2552989995 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Cardiovascular diseases Clinical trials Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Hematocrit Hemoglobin Hemoglobins - metabolism Humans Hypoglycemic Agents - therapeutic use Kidney diseases Medicine Medicine & Public Health Meta-analysis Na+/glucose cotransporter Nephrology Nephrology - Review Patients Placebos Randomized Controlled Trials as Topic Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Systematic review Urology |
| title | Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T14%3A37%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20sodium%E2%80%93glucose%20cotransporter%202%20inhibitors%20on%20hemoglobin%20and%20hematocrit%20levels%20in%20type%202%20diabetes:%20a%20systematic%20review%20and%20meta-analysis&rft.jtitle=International%20urology%20and%20nephrology&rft.au=Kanbay,%20Mehmet&rft.date=2022-04-01&rft.volume=54&rft.issue=4&rft.spage=827&rft.epage=841&rft.pages=827-841&rft.issn=0301-1623&rft.eissn=1573-2584&rft_id=info:doi/10.1007/s11255-021-02943-2&rft_dat=%3Cproquest_cross%3E2552989995%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2639124432&rft_id=info:pmid/34273060&rfr_iscdi=true |